Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-REAL trial of trastuzumab deruxtecan in first-line HER2-positive metastatic breast cancer
2025-521805-41-00Phase 3Authorised
- Sponsor
- SOLTI
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab deruxtecan and pertuzumab in breast cancer, sponsored by SOLTI. Primary endpoints: Time to first subsequent therapy and Time to 10% deterioration in physical functioning. Planned start Feb 2026; status: authorised.
02
Drugs
trastuzumab deruxtecanpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521805-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521805-41-00.